Your browser doesn't support javascript.
loading
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
Perico, Norberto; Remuzzi, Giuseppe; Griffin, Matthew D; Cockwell, Paul; Maxwell, Alexander P; Casiraghi, Federica; Rubis, Nadia; Peracchi, Tobia; Villa, Alessandro; Todeschini, Marta; Carrara, Fabiola; Magee, Bernadette A; Ruggenenti, Piero L; Rota, Stefano; Cappelletti, Laura; McInerney, Veronica; Griffin, Tomás P; Islam, Md Nahidul; Introna, Martino; Pedrini, Olga; Golay, Josée; Finnerty, Andrew A; Smythe, Jon; Fibbe, Willem E; Elliman, Stephen J; O'Brien, Timothy.
Afiliación
  • Perico N; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Remuzzi G; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Griffin MD; Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre for Medical Devices, School of Medicine, University of Galway, Galway, Ireland.
  • Cockwell P; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Maxwell AP; Institute of Ageing and Immunity, University of Birmingham, Birmingham, United Kingdom.
  • Casiraghi F; Queen's University Belfast Centre for Public Health, Belfast, United Kingdom.
  • Rubis N; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Peracchi T; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Villa A; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Todeschini M; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Carrara F; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Magee BA; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Ruggenenti PL; Northern Ireland Histocompatibility and Immunogenetics Laboratory, Belfast City Hospital, Belfast, Northern Ireland.
  • Rota S; Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Cappelletti L; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • McInerney V; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Griffin TP; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Islam MN; Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre for Medical Devices, School of Medicine, University of Galway, Galway, Ireland.
  • Introna M; HRB Clinical Research Facility, University of Galway, Galway, Ireland.
  • Pedrini O; Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre for Medical Devices, School of Medicine, University of Galway, Galway, Ireland.
  • Golay J; Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre for Medical Devices, School of Medicine, University of Galway, Galway, Ireland.
  • Finnerty AA; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Smythe J; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Fibbe WE; Fondazione per la Ricerca Ospedale di Bergamo (FROM), Bergamo, Italy.
  • Elliman SJ; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • O'Brien T; Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre for Medical Devices, School of Medicine, University of Galway, Galway, Ireland.
J Am Soc Nephrol ; 34(10): 1733-1751, 2023 10 01.
Article en En | MEDLINE | ID: mdl-37560967
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Insuficiencia Renal Crónica / Células Madre Mesenquimatosas Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Insuficiencia Renal Crónica / Células Madre Mesenquimatosas Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia